March 7 (Reuters) - Imugene Ltd IMU.AX :
* Manufacturing update
* Updates on manufacturing of its her-vaxx cancer immunotherapy product, currently initiating activity in gastric cancer
* Entire process of her-vaxx cancer immunotherapy product development has resulted in saving of > $500,000 to imugene's bottom line from original budget
* Source text for Eikon